Identification of the DEAD box RNA helicase DDX3 as a therapeutic target in colorectal cancer

Oncotarget

Volumn 6, Issue 29, 2015, Pages 28312-28326

  Heerma van Voss, Marise R ^a,b   Vesuna, Farhad ^a   Trumpi, Kari ^b   Brilliant, Justin ^a   Berlinicke, Cynthia ^c   de Leng, Wendy ^b   Kranenburg, Onno ^b   Offerhaus, Johan ^b   Bürger, Horst ^d   van der Wall, Elsken ^b   van Diest, Paul J ^b   Raman, Venu ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d Institute of Pathology   (Germany)

Author keywords

Colorectal cancer; DEAD box RNA helicases; Small molecule inhibitors; Wnt signaling; catenin

Indexed keywords

ANTINEOPLASTIC AGENT; APC PROTEIN; BETA CATENIN; DDX3 PROTEIN; DEAD BOX PROTEIN; RK 33; SMALL INTERFERING RNA; T CELL FACTOR PROTEIN; TCF4 PROTEIN; UNCLASSIFIED DRUG; AZEPINE DERIVATIVE; BASIC HELIX LOOP HELIX LEUCINE ZIPPER TRANSCRIPTION FACTOR; DDX3X PROTEIN, HUMAN; DDX5 PROTEIN, HUMAN; IMIDAZOLE DERIVATIVE; RK-33 COMPOUND; TCF4 PROTEIN, HUMAN; TRANSCRIPTION FACTOR;

ADULT; AGED; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER INHIBITION; CELL DEATH; CELL NUCLEUS; CELLULAR DISTRIBUTION; COLORECTAL CANCER; COLORECTAL CANCER CELL LINE; CONTROLLED STUDY; CTNNB1 GENE; CYTOPLASM; DRUG SENSITIVITY; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; GENE MUTATION; GENE SILENCING; HUMAN; HUMAN TISSUE; IC50; MAJOR CLINICAL STUDY; MALE; TUMOR SUPPRESSOR GENE; WNT SIGNALING PATHWAY; ANTAGONISTS AND INHIBITORS; CELL SURVIVAL; COLORECTAL NEOPLASMS; DOSE RESPONSE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HCT 116 CELL LINE; HT-29 CELL LINE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; METABOLISM; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; MUTATION; PROCEDURES; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TUMOR CELL LINE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AZEPINES; BASIC HELIX-LOOP-HELIX LEUCINE ZIPPER TRANSCRIPTION FACTORS; BETA CATENIN; CELL LINE, TUMOR; CELL SURVIVAL; COLORECTAL NEOPLASMS; DEAD-BOX RNA HELICASES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HCT116 CELLS; HT29 CELLS; HUMANS; IMIDAZOLES; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; MUTATION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TRANSCRIPTION FACTORS; WNT SIGNALING PATHWAY;

EID: 84944464014     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.4873     Document Type: Article

References (42)

1. American Cancer Society. Cancer Facts & Figures. 2014. (Atlanta: American Cancer Society).
2. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012; 487:330-337.
3. Botlagunta M, Vesuna F, Mironchik Y, Raman A, Lisok A, Winnard P Jr., Mukadam S, Van Diest P, Chen JH, Farabaugh P, Patel AH, Raman V. Oncogenic role of DDX3 in breast cancer biogenesis. Oncogene. 2008; 27:3912-3922.
4. Bol GM, Vesuna F, Xie M, Zeng J, Aziz K, Gandhi N, Levine A, Irving A, Korz D, Tantravedi S, Heerma van Voss MR, Gabrielson K, Bordt EA, Polster BM, Cope L, van der Groep P, et al. Targeting DDX3 with a small molecule inhibitor for lung cancer therapy. EMBO molecular medicine. 2015; 7:648-69
5. Cruciat CM, Dolde C, de Groot RE, Ohkawara B, Reinhard C, Korswagen HC, Niehrs C. RNA helicase DDX3 is a regulatory subunit of casein kinase 1 in Wntbeta-catenin signaling. Science. 2013; 339:1436-1441.
6. Chen HH, Yu HI, Cho WC, Tarn WY. DDX3 modulates cell adhesion and motility and cancer cell metastasis via Rac1-mediated signaling pathway. Oncogene. 2015; 34:2790-800
7. Pugh TJ, Weeraratne SD, Archer TC, Pomeranz Krummel DA, Auclair D, Bochicchio J, Carneiro MO, Carter SL, Cibulskis K, Erlich RL, Greulich H, Lawrence MS, Lennon NJ, McKenna A, Meldrim J, Ramos AH, et al. Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations. Nature. 2012; 488:106-110.
8. Jones DT, Jager N, Kool M, Zichner T, Hutter B, Sultan M, Cho YJ, Pugh TJ, Hovestadt V, Stutz AM, Rausch T, Warnatz HJ, Ryzhova M, Bender S, Sturm D, Pleier S, et al. Dissecting the genomic complexity underlying medulloblastoma. Nature. 2012; 488:100-105.
9. Robinson G, Parker M, Kranenburg TA, Lu C, Chen X, Ding L, Phoenix TN, Hedlund E, Wei L, Zhu X, Chalhoub N, Baker SJ, Huether R, Kriwacki R, Curley N, Thiruvenkatam R, et al. Novel mutations target distinct subgroups of medulloblastoma. Nature. 2012; 488:43-48.
10. Yang L, Lin C, Liu ZR. P68 RNA helicase mediates PDGFinduced epithelial mesenchymal transition by displacing Axin from beta-catenin. Cell. 2006; 127:139-155.
11. Shin S, Rossow KL, Grande JP, Janknecht R. Involvement of RNA helicases p68 and p72 in colon cancer. Cancer research. 2007; 67:7572-7578.
12. Choi YJ, Lee SG. The DEAD-box RNA helicase DDX3 interacts with DDX5, co-localizes with it in the cytoplasm during the G2/M phase of the cycle, and affects its shuttling during mRNP export. Journal of cellular biochemistry. 2012; 113:985-996.
13. He B, Reguart N, You L, Mazieres J, Xu Z, Lee AY, Mikami I, McCormick F, Jablons DM. Blockade of Wnt-1 signaling induces apoptosis in human colorectal cancer cells containing downstream mutations. Oncogene. 2005; 24:3054-3058.
14. Voloshanenko O, Erdmann G, Dubash TD, Augustin I, Metzig M, Moffa G, Hundsrucker C, Kerr G, Sandmann T, Anchang B, Demir K, Boehm C, Leible S, Ball CR, Glimm H, Spang R, et al. Wnt secretion is required to maintain high levels of Wnt activity in colon cancer cells. Nature communications. 2013; 4:2610.
15. de Sousa EM, Vermeulen L, Richel D, Medema JP. Targeting Wnt signaling in colon cancer stem cells. Clinical cancer research: an official journal of the American Association for Cancer Research. 2011; 17:647-653.
16. Anastas JN, Moon RT. WNT signalling pathways as therapeutic targets in cancer. Nature reviews Cancer. 2013; 13:11-26.
17. Oliver PG, LoBuglio AF, Zhou T, Forero A, Kim H, Zinn KR, Zhai G, Li Y, Lee CH, Buchsbaum DJ. Effect of anti-DR5 and chemotherapy on basal-like breast cancer. Breast cancer research and treatment. 2012; 133:417-426.
18. Shih JW, Wang WT, Tsai TY, Kuo CY, Li HK, Wu Lee YH. Critical roles of RNA helicase DDX3 and its interactions with eIF4E/PABP1 in stress granule assembly and stress response. The Biochemical journal. 2012; 441:119-129.
19. Lai MC, Chang WC, Shieh SY, Tarn WY. DDX3 regulates cell growth through translational control of cyclin E1. Molecular and cellular biology. 2010; 30:5444-5453.
20. Hagerstrand D, Tong A, Schumacher SE, Ilic N, Shen RR, Cheung HW, Vazquez F, Shrestha Y, Kim SY, Giacomelli AO, Rosenbluh J, Schinzel AC, Spardy NA, Barbie DA, Mermel CH, Weir BA, et al. Systematic interrogation of 3q26 identifies TLOC1 and SKIL as cancer drivers. Cancer discovery. 2013; 3:1044-1057.
21. Huang JS, Chao CC, Su TL, Yeh SH, Chen DS, Chen CT, Chen PJ, Jou YS. Diverse cellular transformation capability of overexpressed genes in human hepatocellular carcinoma. Biochemical and biophysical research communications. 2004; 315:950-958.
22. Sun M, Song L, Li Y, Zhou T, Jope RS. Identification of an antiapoptotic protein complex at death receptors. Cell death and differentiation. 2008; 15:1887-1900.
23. Chang PC, Chi CW, Chau GY, Li FY, Tsai YH, Wu JC, Wu Lee YH. DDX3, a DEAD box RNA helicase, is deregulated in hepatitis virus-associated hepatocellular carcinoma and is involved in cell growth control. Oncogene. 2006; 25:1991-2003.
24. Chao CH, Chen CM, Cheng PL, Shih JW, Tsou AP, Lee YH. DDX3, a DEAD box RNA helicase with tumor growth-suppressive property and transcriptional regulation activity of the p21waf1/cip1 promoter, is a candidate tumor suppressor. Cancer research. 2006; 66:6579-6588.
25. Wu DW, Lee MC, Wang J, Chen CY, Cheng YW, Lee H. DDX3 loss by p53 inactivation promotes tumor malignancy via the MDM2/Slug/E-cadherin pathway and poor patient outcome in non-small-cell lung cancer. Oncogene. 2014; 33:1515-1526.
26. Wu DW, Liu WS, Wang J, Chen CY, Cheng YW, Lee H. Reduced p21(WAF1/CIP1) via alteration of p53-DDX3 pathway is associated with poor relapse-free survival in early-stage human papillomavirus-associated lung cancer. Clinical cancer research: an official journal of the American Association for Cancer Research. 2011; 17:1895-1905.
27. Heerma van Voss MR, van Kempen PMW, Noorlag R, van Diest PJ, Willems SM, Raman V. DDX3 has divergent roles in head and neck squamous cell carcinomas in smoking versus non-smoking patients. Oral diseases. 2015; 21:270-271.
28. Lee CH, Lin SH, Yang SF, Yang SM, Chen MK, Lee H, Ko JL, Chen CJ, Yeh KT. Low/negative expression of DDX3 might predict poor prognosis in non-smoker patients with oral cancer. Oral diseases. 2014; 20:76-83.
29. COSMIC: Catalogue of Somatic Mutations in Cancer. Sanger Institute, http://cancer.sanger.ac.uk/cancergenome/ projects/cosmic/, last accessed: 2015; March 21st.
30. Sun M, Zhou T, Jonasch E, Jope RS. DDX3 regulates DNA damage-induced apoptosis and p53 stabilization. Biochimica et biophysica acta. 2013; 1833:1489-1497.
31. Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, Sedivy JM, Kinzler KW, Vogelstein B. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science. 1998; 282:1497-1501.
32. Chan TA, Wang Z, Dang LH, Vogelstein B, Kinzler KW. Targeted inactivation of CTNNB1 reveals unexpected effects of beta-catenin mutation. Proceedings of the National Academy of Sciences of the United States of America. 2002; 99:8265-8270.
33. Emmink BL, Van Houdt WJ, Vries RG, Hoogwater FJ, Govaert KM, Verheem A, Nijkamp MW, Steller EJ, Jimenez CR, Clevers H, Borel Rinkes IH, Kranenburg O. Differentiated human colorectal cancer cells protect tumorinitiating cells from irinotecan. Gastroenterology. 2011; 141:269-278.
34. Halling-Brown MD, Bulusu KC, Patel M, Tym JE, Al-Lazikani B. canSAR: an integrated cancer public translational research and drug discovery resource. Nucleic acids research. 2012; 40:D947-956.
35. Angus AG, Dalrymple D, Boulant S, McGivern DR, Clayton RF, Scott MJ, Adair R, Graham S, Owsianka AM, Targett-Adams P, Li K, Wakita T, McLauchlan J, Lemon SM, Patel AH. Requirement of cellular DDX3 for hepatitis C virus replication is unrelated to its interaction with the viral core protein. The Journal of general virology. 2010; 91:122-132.
36. Trumpi K, Egan DA, Vellinga TT, Borel Rinkes IH, Kranenburg O. Paired image-and FACS-based toxicity assays for high content screening of spheroid-type tumor cell cultures. FEBS open bio. 2015; 5:85-90.
37. Vesuna F, Lisok A, Kimble B, Domek J, Kato Y, van der Groep P, Artemov D, Kowalski J, Carraway H, van Diest P, Raman V. Twist contributes to hormone resistance in breast cancer by downregulating estrogen receptor-alpha. Oncogene. 2012; 31:3223-3234.
38. van de Wetering M, Sancho E, Verweij C, de Lau W, Oving I, Hurlstone A, van der Horn K, Batlle E, Coudreuse D, Haramis AP, Tjon-Pon-Fong M, Moerer P, van den Born M, Soete G, Pals S, Eilers M, et al. The betacatenin/ TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell. 2002; 111:241-250.
39. Yuan JS, Reed A, Chen F, Stewart CN Jr. Statistical analysis of real-time PCR data. BMC bioinformatics. 2006; 7:85.
40. Kodach LL, Wiercinska E, de Miranda NF, Bleuming SA, Musler AR, Peppelenbosch MP, Dekker E, van den Brink GR, van Noesel CJ, Morreau H, Hommes DW, Ten Dijke P, Offerhaus GJ, Hardwick JC. The bone morphogenetic protein pathway is inactivated in the majority of sporadic colorectal cancers. Gastroenterology. 2008; 134:1332-1341.
41. The Medical Research Involving Human Subjects Act [In Dutch Wet medisch-wetenschappelijk onderzoek met mensen, WMO]I, Burgerlijk Wetboek, (1998), BWBR0009408, Available at: http://wetten.overheid.nl/ BWBR0009408/geldigheidsdatum_21-03-2015/:1998.
42. van Diest PJ. No consent should be needed for using leftover body material for scientific purposes. For. BMJ. 2002; 325:648-651.